ACC 2024 | IVUS-DCB

Drug-coated balloons (DCB) have proven to be effective in the treatment of femoropopliteal pathology, although they entail complications such as recoil, residual stenosis, and dissection.

ACC 2024

Their outcomes could be improved through proper and enhanced vessel preparation, both before and after the procedure. Intravascular ultrasound (IVUS) offers the advantage of characterizing plaque and assessing vessel diameter.

The aim of this study was to compare IVUS-guided angioplasty vs. conventional angiography in DCB (IN.PACT, Medtronic) treatment of femoropopliteal disease. Researchers included a total of 237 patients from 7 centers in Korea; these subjects were randomized to IVUS (n=119) and angiography (n=118). The primary endpoint was primary patency (PP) at 12 months.

The average age was 69 years; 85.7% of patients were men, 74.8% had claudication, and the rest had critical limb ischemia. Regarding characteristics, most lesions were TASC II C/D (67.2%).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

Technical success was achieved in 76.5% of IVUS patients and 61% of those undergoing angiography. Post-procedure ankle-brachial index (ABI) was 0.99 and 0.93, respectively. When evaluating PP, better outcomes were observed in the IVUS arm (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.25-0.85; Log-rank P= 0.01). Additionally, considering secondary events, IVUS-guided treatment showed better results in terms of revascularization-free vessel (HR, 0.41; 95% CI, 0.19-0.90; Log-rank P= 0.03) and sustained clinical improvement (HR, 0.45; 95% CI, 0.23-0.86; Log-rank P=0.02).

In conclusion, IVUS guidance significantly improved DCB treatment outcomes in femoropopliteal disease, with better primary patency, greater freedom from new revascularization, and clinical improvement at 12 months.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparación de angioplastia dirigida por IVUS vs dirigido por angiografía en el tratamiento con balón con drogas para territorio femoropoplíteo. 

Reference: Presentado por Dr. Young-Guk Ko en ACC.24 Late-Breaking Clinical Trials, 6-8 de abril, Atlanta.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...